BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37358613)

  • 1. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
    Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
    Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
    Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
    Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.
    Ding Y; Rao SX; Meng T; Chen C; Li R; Zeng MS
    Eur Radiol; 2014 Apr; 24(4):959-66. PubMed ID: 24463697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-contrast T1ρ dispersion versus Gd-EOB-DTPA-enhanced T1mapping for the risk stratification of non-alcoholic fatty liver disease in rabbit models.
    Yang R; Chen Z; Pan J; Yang S; Hu F
    Magn Reson Imaging; 2024 Apr; 107():130-137. PubMed ID: 38278311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis.
    Wu Z; Matsui O; Kitao A; Kozaka K; Koda W; Kobayashi S; Ryu Y; Minami T; Sanada J; Gabata T
    J Magn Reson Imaging; 2013 May; 37(5):1137-43. PubMed ID: 23172731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
    Xie Y; Zhang H; Jin C; Wang X; Wang X; Chen J; Xu Y
    Magn Reson Imaging; 2018 May; 48():34-41. PubMed ID: 29278765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.
    Akai H; Kiryu S; Ohta Y; Yasaka K; Nakano Y; Inoue Y; Ohtomo K
    Magn Reson Imaging; 2017 May; 38():123-128. PubMed ID: 28062263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
    Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
    Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats.
    Okada M; Katsube T; Kumano S; Kagawa Y; Araki T; Tsuda N; Okuaki T; Imaoka I; Tanigawa N; Ishii K; Murakami T
    Acta Radiol; 2011 Jul; 52(6):658-64. PubMed ID: 21498305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
    Tsuda N; Okada M; Murakami T
    Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study.
    Bastati N; Feier D; Wibmer A; Traussnigg S; Balassy C; Tamandl D; Einspieler H; Wrba F; Trauner M; Herold C; Ba-Ssalamah A
    Radiology; 2014 Jun; 271(3):739-47. PubMed ID: 24576046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver-fat and liver-function indices derived from Gd-EOB-DTPA-enhanced liver MRI for prediction of future liver remnant growth after portal vein occlusion.
    Barth BK; Fischer MA; Kambakamba P; Lesurtel M; Reiner CS
    Eur J Radiol; 2016 Apr; 85(4):843-9. PubMed ID: 26971433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a predictor of insufficient enhancement during the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging.
    Cui E; Long W; Luo L; Hu M; Huang L; Chen X
    Acta Radiol; 2017 Oct; 58(10):1174-1181. PubMed ID: 28090793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Enhancement in Gadoxetate Disodium-Enhanced Liver MRI as an Imaging Biomarker in the Diagnosis of Non-Alcoholic Fatty Liver Disease in Pediatric Obesity.
    Hojreh A; Lischka J; Tamandl D; Ramazanova D; Mulabdic A; Greber-Platzer S; Ba-Ssalamah A
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application Progress of Gd-EOB-DTPA-Enhanced MRI T1 Mapping in Hepatic Diffuse Diseases.
    Wen X; Feng X; Kang Y; Xu L
    Curr Med Imaging; 2022; 18(12):1276-1281. PubMed ID: 34847846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
    Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
    Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.